Elanco (ELAN) CFO receives 8.216 deferred stock units as compensation award

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

VanHimbergen Robert M reported acquisition or exercise transactions in this Form 4 filing.

Elanco Animal Health EVP and CFO Robert M. VanHimbergen received a grant of 8.216 deferred stock units, each linked to one share of Elanco common stock or its cash equivalent. Following this grant, his reported deferred stock unit balance is 48.7929 units. These units will settle in cash or stock after his employment ends or in a specified future year under the company’s Executive Deferral and Stock Match Plan, so this filing reflects compensation rather than an open‑market trade.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider VanHimbergen Robert M

Role EVP and CFO

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	8.216	$23.98	$197.02

Holdings After Transaction: Deferred Stock Units — 48.793 shares (Direct)

Footnotes (1)

Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

03/24/2026 - 04:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

VanHimbergen Robert M

(Last)

(First)

(Middle)

C/O ELANCO ANIMAL HEALTH INCORPORATED

450 ELANCO CIRCLE

(Street)

INDIANAPOLIS

INDIANA

46221

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Deferred Stock Units	⁽¹⁾	03/20/2026		A		8.216		⁽²⁾	⁽²⁾	Common Stock	8.216	$23.98	48.7929	D

Explanation of Responses:

1. Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.

2. Deferred stock units settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

	/s/ Amy C. Seidel, as Attorney-in-Fact for Robert M. VanHimbergen	03/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Elanco Animal Health (ELAN) report for its CFO?

Elanco reported that EVP and CFO Robert M. VanHimbergen received 8.216 deferred stock units as a compensation grant. These derivative units are tied to Elanco common stock and increase his deferred equity-based holdings without involving any open-market purchase or sale of shares.

What are the deferred stock units granted to Elanco (ELAN) CFO Robert VanHimbergen?

The 8.216 deferred stock units represent rights to receive either one share of Elanco common stock or the cash equivalent per unit. They function as deferred compensation, giving the executive equity-linked value without immediate share delivery or cash payment at the grant date.

When will the Elanco (ELAN) CFO’s deferred stock units be settled?

The deferred stock units will settle in cash or Elanco common shares after the CFO’s employment terminates or in a specified future year. Settlement timing follows the company’s Executive Deferral and Stock Match Plan, which governs when and how these deferred awards are paid.

How many deferred stock units does the Elanco (ELAN) CFO hold after this grant?

After receiving the 8.216-unit grant, the Elanco EVP and CFO is reported as holding 48.7929 deferred stock units. This figure reflects his outstanding balance of these equity-linked compensation instruments as of the transaction date disclosed in the Form 4.

Does the Elanco (ELAN) CFO Form 4 show any open-market buying or selling of shares?

The Form 4 shows no open-market purchases or sales by the CFO. It records only an acquisition coded as a grant of 8.216 deferred stock units, which are compensation awards rather than discretionary stock trades in the public market.